# JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

Source: https://onco.cc/trials/nct06586866/  
OnCo record `nct06586866` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by JenKem Technology Co., Ltd., not yet recruiting.

## Summary

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases is a phase 2, interventional study registered as NCT06586866 by JenKem Technology Co., Ltd., with a registry enrolment figure of 25 participants, started 2024-09-26 and due to reach its primary completion in 2026-05-26. Interventions recorded: JK-1201I. Conditions listed: Triple Negative Breast Cancer (TNBC); Brain Metastasases. Triple-negative eligibility wording from the registry: "Histological or cytological confirmation of triple-negative breast cancer (TNBC)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06586866
- Phase: 2
- Setting: A Multicenter, Single-Arm, Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases
- Sponsor: JenKem Technology Co., Ltd.
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06586866: https://clinicaltrials.gov/study/NCT06586866

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Brain metastases (intracranial disease)](https://onco.cc/terms/brain-metastases/), [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06586866.json